Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor + Pegaspargase + Dexamethasone in Early Stage NK/T-Cell Lymphoma
NCT06559553Phase 2Recruiting
- Start
- Sep 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of selinexor in Natural killer T-cell lymphoma (NKTL). Started Sep 2024; status: recruiting.
02
Drugs
selinexor
03
Conditions
Natural killer T-cell lymphoma (NKTL)
Beyond the preview
Go deeper on NCT06559553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06559553.